<DOC>
	<DOCNO>NCT00817284</DOCNO>
	<brief_summary>Significant activity ( radiographic response rate approximately 60 % ) recently demonstrate phase II study patient relapse GBM combine use Irinotecan ( CPT-11 ) bevacizumab . The 6-month progression-free survival rate 30 % median survival duration 9 month . The current first line therapy GBM patient follow initial surgical resection/debulking concomitant use cerebral radiotherapy orally available alkylating agent temozolomide , follow temozolomide 6 month post-radiotherapy . Considering significant activity combination Bevacizumab + irinotecan patient recurrent GBM , consider activity temozolomide GBM , propose combination Bevacizumab + Temozolomide may also active regimen . Bevacizumab + Temozolomide display non-overlapping toxicity clinically thus combine use without significant dose-reductions seem rational . The toxicity combine use two drug prior radiotherapy , well toxicity administer together radiotherapy , evaluate . This study try identity whether Bevacizumab Irinitecan Bevacizumab Temozolomide experimental arm future phase III comparison standard care concomitant Temozolomide radiotherapy .</brief_summary>
	<brief_title>Bevacizumab Irinotecan Bevacizumab Temozolomide With Concomitant Radiotherapy Primary Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Inclusion criterion : Signed informed consent Histological verify primary glioblastoma multiforme No prior therapy GBM , except primary surgical resection biopsy PS 02 Age &gt; 18 Expected survival &gt; 3 month Adequate liver , renal bonemarrow function , determine : Thrombocytes &gt; 100 x 109/liter Hemoglobin &gt; 6.2 mmol/liter Leukocytes &gt; 3 x 109/liter Neutrophil granulocyte &gt; 1.5 x 109/liter ASAT and/or ALAT &lt; 3 x upper normal limit Bilirubin &lt; 1.5 x upper normal limit Serumcreatinin &lt; upper normal limit glomerular filtration rate &gt; 60 ml/min ( correct age ) determine measurement clearance CrEDTA APTT &lt; upper normal limit INR &lt; upper normal limit Fertile woman childbearing age must use proper anticonception ( oral contraceptive , IUD and/or condom ) . Fertile men must use condom No sign cerebral bleed cerebral MRscanning baseline . Exclusion criterion : Previous therapy GBM , include radiotherapy use biological `` target '' drug , e.g . drug target VEGF EGFR pathway Concurrent use medication affect interpretation result study , e.g . use immunosuppressive drug , except corticosteroid Conditions ( medical , social physical ) may compromise proper information and/or followup Other concurrent previous cancer within 5 year , except adequately treat basal planocellular skin cancer , cervical carcinoma situ Significant heart disease ( accord New York Heart Association class II severe ) , clinically significant arrhythmia unstable angina pectoris/acute myocardial infarction within last 6 month Clinical significant peripheral arterial disease Known suspect disorder coagulation concurrent therapy ASA , NSAID clopidogrel Major surgery , open biopsy great trauma , expectation thereof , within 28 day prior start therapy Minor surgery needle biopsy , expectation thereof , within 7 day prior start therapy Known suspect abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month prior start therapy Chronic inflammatory intestinal disease and/or intestinal obstruction Known active HIV Hepatitis B/C infection Concurrent ongoing significant infection diabetes mellitus adequately control medically Clinically significant nonhealing ulcer Active ventricular duodenal ulcer within 6 month prior start therapy Recent bonefracture ( &lt; 3 month ) Pregnancy lactation Need systemic anticoagulant therapy time start therapy Blood pressure &gt; 150/100 mmHg ( patient allow receive proper antihypertensive medication ) Proteinuria â‰¥ 1 gram/day Known allergy toward irinotecan ( related substance ) vehicle Known allergy toward temozolomide ( related substance ) vehicle Known allergy toward bevacizumab ( related substance ) vehicle</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Newly diagnose patient glioblastoma multiforme .</keyword>
	<keyword>Performance status 0-2 .</keyword>
</DOC>